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Atrial fibrillation (AF) is the most prevalent sustained arrhythmia in 
Australia and globally. It is perhaps the strongest independent clinical 
predictor of stroke, multiplying the risk almost five-fold and accounting 
for about a fifth of total strokes.1,2
In Australia, stroke causes about 
33,700 hospital admissions per year, 
and has a 79% risk of death within 
10 years of a first stroke. A key strategy 
for reducing the associated burden of 
disease is to prevent stroke in patients 
with AF. This article will discuss the use 
of novel oral anticoagulants (NOACs, 
also referred to as direct OACs, or 
DOACs) for stroke prevention in patients 
with non-valvular atrial fibrillation and 
one additional risk for stroke.
Pathophysiology and 
epidemiology
The prevalence of AF is between 1% 
and 2% in most developed countries, 
but over 10% in the population over 
80 years.2 Established risk factors for 
AF include older age, male gender, 
hypertension, valvular heart disease, left 
ventricular systolic dysfunction, obesity, 
diabetes mellitus and excess alcohol 
consumption.3 Evidence for the effects 
of several further risk factors such as 
endurance physical activity, obstructive 
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LEARNING OBJECTIVES
After reading this article, pharmacists should be 
able to:
• Describe the role of oral anticoagulants in the 
management of atrial fibrillation
• Discuss current clinical evidence for the use of 
novel oral anticoagulants
• Explain precautions in the use of novel oral 
anticoagulants.
Competency standards (2010) addressed: 6.1, 6.2, 
6.3, 7.1, 7.2, 7.3.
Accreditation number: CAP150101H
The role of novel oral 
anticoagulants in atrial 
fibrillation
BY KEVIN MC NAMARA & ROCHELLE GELLATLY
Th
is
 a
rt
ic
le
 h
as
 b
ee
n 
in
de
pe
nd
en
tly
 re
se
ar
ch
ed
 a
nd
 p
ee
r r
ev
ie
w
ed
.
sleep apnoea, prehypertension and 
chronic kidney disease is emerging.3 
Normal heart rhythm (sinus rhythm) 
is initiated via electrical impulses 
from the sinoatrial (SA) node. 
This eventually leads to contraction 
of the upper chambers of the heart 
(the atria), then ventricular contraction 
and pumping of blood systemically. 
AF arises from disturbance in the 
normal electrical signals in the atria 
through the introduction of aberrant 
electrical mechanisms known as 
drivers.4 Local ectopic drivers, mainly 
from the pulmonary vein, are thought 
to predominate in paroxysmal 
(i.e. intermittent) AF, usually the 
initial AF presentation and defined by 
self-termination within a few days.4 
These initial isolated drivers can cause 
atrial remodelling, which in turn can 
further distort electrical conduction and 
contraction. Persistent and subsequently 
permanent AF may result. In persistent 
AF, the arrhythmia has been present for 
at least a week but sinus rhythm may 
still be restored. In permanent AF the 
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condition is either not reversible or is 
unsafe to reverse and the clinical focus 
is to limit complications.4,5 The absence 
of regular atrial contraction leads to 
pooling of blood in the atria, more 
specifically in the left atrial appendage 
and increases risk of thrombus 
formation. Classic AF symptoms include 
dizziness, chest pain, breathlessness 
and a thumping heartbeat, but it can 
also be asymptomatic. Thrombi that 
break free can lead to strokes if they 
enter the cerebrovascular circulation. 
Anticoagulant therapy to reduce 
thrombus formation and subsequent 
stroke risk is a key treatment strategy.2
General principles of 
pharmacotherapy
The key medication management 
decisions in AF are (a) whether to 
adopt a rhythm control or rate control 
strategy, and (b) whether to initiate 
anticoagulation.
Rate control or rhythm control
While prospective trials do not 
suggest a clearly superior option in 
terms of mortality, rhythm control 
is often favoured over rate control 
for patients that are symptomatic as 
it confers significant symptomatic 
benefits.6 Rhythm control is particularly 
considered for patients who are younger 
and without advanced structural cardiac 
disease.7,8 Catheter ablation may be 
considered to restore sinus rhythm in 
suitable symptomatic patients who are 
refractory to antiarrhythmic drugs.7
By contrast rate control is preferred 
for older patients, if no AF symptoms 
exist, if activities of daily living are not 
affected and they cannot return to 
sinus rhythm. This option has a lower 
likelihood of adverse drug events.6 
The ultimate decision for either rate or 
rhythm control depends on the evolving 
condition, patient response to therapy 
and changing patient preferences, or a 
combination of these.
Initiating oral anticoagulant 
therapy (OAC)
OAC use for AF should be based on a 
patient’s estimated stroke risk, measured 
using a validated risk score. Previous 
Australian guidelines for AF management 
have recommended estimation of stroke 
risk using the CHADS2 score (Table 1).
9 A 
CHADS2 score of two or more indicates a 
need for anticoagulation, while a score 
of 1 suggests it should be considered. 
However, because it excludes several 
common risk factors for stroke in AF, 
CHADS2 scores of 0 can still involve an 
unacceptably high risk of stroke and 
warrant treatment.10,11
More accepted practice recently is to 
assess stroke risk using the CHA2DS2-
VASc score (Table 1).10,12 This lowers 
the anticoagulation threshold to ≥1, 
and increases scope for the indication 
by adding an extra point for age over 
75 years. It also allocates a point each 
for female gender, presence of vascular 
disease and age 65–74 years. In essence 
CHA2DS2-VASc shifts the focus towards 
identifying patients who are ‘truly low 
risk’ and do not need antithrombotic 
therapy.10,12 There is weak evidence 
of cardiovascular disease or mortality 
benefit from antiplatelet therapy 
and its use is discouraged – however, 
antiplatelet use may be justified for 
eligible patients who refuse an OAC.2
A formal bleeding risk assessment is 
essential for patients with AF. The widely 
validated HAS-BLED score (Figure 1) is 
most commonly recommended in recent 
major guidelines. Because patients at 
Table 1. Comparison of key stroke risk scores (adapted from Camm et al.)2,10
Algorithm components CHADS2 points CHA2DS2-VASc points
Congestive heart failure/
left ventricular dysfunction  
(ejection fraction ≤40%)
1 1
Hypertension 1 1
Age ≥75 years 1 2
Diabetes mellitus 1 1
Previous stroke, TIA or systemic 
embolism
2 2
Vascular disease* - 1
Age 65–74 years - 1
Female gender - 1
Maximum score 6 9
* Prior myocardial infarction, peripheral artery disease, aortic plaque
Risk score Adjusted stroke rate (% 
per year, CHADS2)**
Adjusted stroke rate (% 
per year, CHA2DS2-VASc)**
0 1.9 0
1 2.8 1.3
2 4.0 2.2
3 5.9 3.2
4 8.5 4.0
5 12.5 6.7
6 18.2 9.8
7 NA 9.6
8 NA 6.7
9 NA 15.2
** From a hospitalised cohort, as presented by Camm et al 2010.2 Actual stroke rates may vary between cohorts
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Bleeding risk factor HAS-BLED points
H Hypertension 1
A Abnormal renal and liver function (1 point each) 1 or 2
S Stroke 1
B Bleeding 1
L Labile INRs 1
E Elderly (e.g. age >65 years) 1
D Drugs or alcohol (1 point each) 1 or 2
Maximum HAS-BLED score 9 points
Figure 1. The HAS-BLED bleeding risk score for use in AF (adapted from Camm et al.)2,10
increased risk of bleeding often derive 
greater benefit from anticoagulation, 
elevated HAS-BLED scores are not 
considered an absolute contraindication 
for anticoagulation and clinical judgment 
is required. In particular patients with a 
HAS-BLED score ≥3 should be carefully 
reviewed to minimise modifiable risk 
factors for bleeding (e.g. withdraw aspirin 
because of no additional benefit, control 
hypertension, manage labile INRs or 
alcohol intake).7,10
Anticoagulant selection
Patients with an indication for OAC 
have a choice between warfarin or a 
NOAC. NOACs are only indicated for 
patients with non valvular AF, defined 
as AF in the absence of rheumatic mitral 
stenosis, a mechanical or bioprosthetic 
heartvalve, or mitral valve repair.12 
There is no evidence of clinical benefits 
of NOACs over warfarin in valvular AF. 
Trials have not been conducted for some 
key forms of valvular AF (e.g. mitral 
valve or rheumatic heart disease), and 
the RE-ALIGN trial of warfarin versus 
dabigatran therapy for patients with 
mechanical valves, found an excess 
of both thromboembolic events and 
bleeding in the dabigatran group.13
According to meta-analyses of 
29 randomised controlled trials (RCTs), 
dose-adjusted warfarin reduces stroke 
risk in non-valvular AF by 64% and 
all-cause mortality by 26%, relative 
to placebo.14 However, therapy with 
warfarin is clinically challenging. Plasma 
levels can vary considerably and efficacy 
at an individual level heavily depends 
on the proportion of time within 
therapeutic INR ranges (TTR), which is 
ideally between 2.0 and 3.0. Regular 
INR monitoring is required to minimise 
bleeding and thromboembolic risks. 
Because warfarin has a considerable lag 
time in its onset of action and inhibits 
several factors within the clotting 
cascade, dosage adjustments are more 
complex than for NOACs. Warfarin also 
has a broad range of drug-drug and 
drug-food interactions.
Key RCT findings for NOACs with 
Pharmaceutical Benefits Scheme 
(PBS) listings are outlined in Table 3. 
Stroke risk, study design and bleeding 
definition vary between studies. 
For several reasons, NOACs are 
increasingly preferred over warfarin 
as anticoagulant therapy for many 
patients experiencing non-valvular 
AF.2,7 They target specific components 
further along the clotting cascade 
– dabigatran as a direct thrombin 
inhibitor, rivaroxaban and apixaban 
(also edoxaban, currently unlicensed 
in Australia) as factor Xa inhibitors. 
This promotes a quicker onset of 
action (full anticoagulation 2–3 hours 
after administration compared 
with five days for warfarin), more 
predictable anticoagulation, and fewer 
interactions with food or drugs.10 
A stable, dose-related anticoagulant 
effect suggests fixed doses are possible 
(see Table 2 for recommended doses). 
Additionally, NOACs appear to be at least 
as effective as warfarin at reducing stroke 
risk in patients with non-valvular AF. 
The outcomes of these trials are 
promising in the crucial areas of 
stroke outcomes and bleeding risk, 
and suggest overall clinical benefit 
from NOACs. However, these are 
new therapies with evidence from 
only a single major trial each, with 
heterogeneous trial design and 
outcomes, and the degree of benefit 
for an individual patient needs to be 
scrutinised. This raises some salient 
issues to communicate to patients in 
order to achieve a balanced perspective 
– efficacy and safety.
Efficacy
These trials were designed to 
demonstrate ‘non-inferiority’ against 
warfarin therapy – such trials have 
methodological limitations when 
compared with trials to demonstrate 
superiority. 
The relative advantage of NOACs over 
warfarin depends on the quality of 
warfarin management. The mean TTR in 
the trials listed above varied from 55% 
to 68%. By consensus TTRs of at least 
65% are the benchmark for practice18 
hence some of these trials fell short 
Table 2. Dosing of novel oral anticoagulants22
Degree of renal 
impairment
Dabigatran Rivaroxaban Apixaban
Normal 150 mg bd 20 mg od 5 mg bd
Moderate 110 mg bd*
(CrCl 30–50 mL/min)
15 mg od
(CrCl 30–49 mL/min)
2.5 mg bd if two of:
Age ≥80 years 
Body weight≤ 60 kg
SCr≥ 133 micromol/L
Severe Contraindicated at 
CrCl <30 mL/min
Contraindicated at 
CrCl <30 mL/min
Contraindicated at 
CrCl <25 mL/min
od = once daily; bd = twice daily; CrCl = creatinine clearance 
* Dabigatran 110 mg bd is also indicated for patients > 75 years, and should be considered for patients with 
high risk of bleeding.
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overall. By contrast, the Australian trial 
centres involved with RE-LY had the 
highest mean TTRs globally (mean 
74%),19 and were among the best of 
45 countries in ROCKET-AF achieving a 
similar TTR.20 Secondary analysis of the 
RE-LY trial suggested that dabigatran 
benefits in terms of mortality and 
composite cardiovascular endpoints 
are uncertain when compared with 
the top quartile of trial centres with a 
mean TTR greater than 72.6%.19 A recent 
examination of INR control for 1137 
Tasmanians found a mean TTR of 69.1%, 
suggesting that Australian management 
is indeed of a high quality. Hence, 
improved clinical outcomes with NOACs 
are not confirmed for patients likely to 
have excellent INR control.21
Safety
As well as its gastrointestinal bleeding 
risk, dabigatran caused dyspepsia in 
approximately 11% of trial patients.22 
Variable pharmacokinetics have been 
identified for dabigatran which might 
cause either elevated or sub-therapeutic 
blood concentrations for some patients 
(increasing bleeding risk or stroke risk 
respectively).23 As with all new drugs, 
the safety and adverse event profile of 
NOACS continues to be refined through 
post-marketing surveillance.
There is not yet any marketed antidote 
to reverse bleeding associated with 
NOACs, although options are under 
investigation. This may be relevant 
for example, in patients scheduled for 
surgery or who have serious bleeding.
All NOACS have a degree of renal 
clearance, especially dabigatran. 
Major clinical trials have included only a 
few patients with severe kidney disease. 
Less evidence exists to support use in 
this subgroup, and it will very often be 
contraindicated (see Table 2). 
In a couple of other situations warfarin 
therapy remains a clear preference for 
non-valvular AF:
• Patients already taking warfarin 
with stable INRs, adequate therapy 
adherence and no adverse events. 
The likely cost-effectiveness 
advantages of NOACs may be reduced 
or eliminated if switching such 
patients from warfarin.24
• Patients who are ineligible for subsidy. 
Current PBS criteria for use of NOACs 
require a diagnosis of non-valvular AF 
and a score of ≥1 based on the older 
CHADS2 scores. Hence some women 
“OAC USE FOR AF SHOULD BE BASED ON A PATIENT’S ESTIMATED 
STROKE RISK, MEASURED USING A VALIDATED RISK SCORE.”
Table 3. Key randomised controlled trials comparing outcomes for warfarin with NOACs listed on the Pharmaceutical Benefits Scheme
NOAC (trial) α Follow-up 
period
Mean 
CHADS2 
score
NOAC annual stroke 
and systemic embolism 
rates versus adjusted-
dose warfarin
Bleeding rates 
(annual) versus 
warfarin
Annual mortality 
rate versus 
warfarin
Mean time in 
therapeutic rage 
for warfarin trial 
arm
Dabigatran (RE-LY 
trial)15 
(n = 12,098)
2 years 2.1 Dabigatran 150 mg 
BD: significantly lower 
(1.11% vs. 1.69%)
Dabigatran 110 mg BD: 
non-inferior (1.53% vs 
1.69%)
Dabigatran 150 mg 
BD: no significant 
difference
Dabigatran 110 mg 
BD: significantly 
lower (2.71% vs. 
3.36%)
No significant 
mortality 
benefit for either 
dabigatran arm 
64%
Rivaroxaban 
(ROCKET-AF trial)16 
(n = 14,264)
2 years 3.5 (score 
of 2+ 
required for 
eligibility)
Rivaroxaban 15–20 mg 
daily:**  non-inferior 
(1.7% vs. 2.2%)
Rivaroxaban 
15–20 mg daily:**  
no significant 
difference
No significant 
mortality benefit 
for rivaroxaban
55%
Apixaban 
(ARISTOTLE trial)17 
(n = 18,201)
1.8 years 2.1 Apixaban 2.5–5 
mg twice daily:** 
significantly lower 
(1.27% vs. 1.60%)
Apixaban 2.5–5 
mg twice daily:** 
significantly lower 
(2.13% vs. 3.09%)
Significantly lower 
all-cause mortality 
rate with apixaban 
(3.52% vs. 3.94%)
62%
α Stroke risk, study design and bleeding definition vary between studies.
** Apixaban 2.5 mg/rivaroxaban 15 mg used only for trial subgroups meeting certain criteria (see Table 2 for details)
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Table 4. Key drug-drug interactions for direct oral anticoagulants22
Dabigatran* Rivaroxaban Apixaban
Antithrombotic 
therapy
Avoid with other anticoagulants or platelet aggregation agents
Inducers Avoid with PGP 
inducers  
(e.g. rifampicin)
Strong CYP3A4 
inducers – caution 
advised
Strong inducers 
of both CYP3A4 
and PGP – caution 
advised
Inhibitors Avoid with:
• PGP inhibitors 
(e.g. systemic 
ketoconazole, 
dronedarone, 
oral verapamil**
Avoid with:
• Azole antimycotics 
(except fluconazole)
• Protease Inhibitors 
(e.g. ritonavir)
Avoid with:
• Azole antimycotics 
(except fluconazole)
• Protease Inhibitors 
(e.g. ritonavir).
*dabigatran is not affected by CYP3A4 inhibition/induction; **simultaneous initiation (check product 
information for further information)
and patients with vascular disease 
deemed appropriate for NOACs 
according to European and American 
guidelines are ineligible in Australia.
• Whatever choice of OAC is 
made, periodic re-evaluation is 
recommended as patients’ bleeding 
and stroke risks can change over time, 
patient preferences may evolve and 
more evidence regarding NOACs may 
become clearer.
Using NOACs
If a NOAC is deemed appropriate, the 
absence of head-to-head trials makes it 
impossible to say which agent is best. 
Each has their pros and cons and a 
degree of clinical judgment and patient 
preference is required.
Rivaroxaban is the only NOAC available 
on the PBS that is taken once daily, 
possibly promoting better adherence. 
Higher doses of rivaroxaban (15 mg 
and 20 mg) need to be taken with food 
to increase its bioavailbility. Patients 
taking dabigatran in the RE-LY trial also 
had a higher rate of dyspepsia than 
warfarin and higher rates of therapy 
discontinuation.15 Due to its hygroscopic 
nature dabigatran capsules must not be 
removed from the original packaging 
prior to administration, perhaps making 
it less practical for use with dose 
administration aids.
All NOACs are metabolised to some 
extent by the kidneys, in particular 
dabigatran which is 80% renally 
cleared.25 Use in patients with any 
level of renal impairment should be 
undertaken with caution and monitored 
to ensure renal function remains 
adequate, and an appropriate dose is 
prescribed. None of the key trials listed 
above examined use in severe renal 
impairment. Dosage adjustment details 
are outlined in Table 2. 
Potential drug-drug interactions also 
need to be considered (see Table 4). 
Rivaroxaban and apixaban are 
metabolised by cytochrome P450 
3A4 (CYP3A4) and are substrates of 
P-glycoprotein (PGP). In contrast, 
dabigatran is not a substrate of 
cytochrome P450 enzymes, but is a 
substrate of PGP. In general, dabigatran 
is contraindicated with concurrent use 
of strong PGP inhibitors. Strong inducers 
of PGP can reduce efficacy of dabigatran 
so should also be avoided. Rivaroxaban 
and apixaban are contraindicated with 
drugs that are both inhibitors of PGP 
and CYP3A4. Use caution when using 
strong inducers of PGP and/or CYP3A4 
in conjunction with these agents due to 
a reduction in efficacy.
Role of the pharmacist
Both the decision to treat with a NOAC 
instead of warfarin, and the NOAC agent 
of choice, are quite complicated and 
should be a shared decision with the 
doctor and patient. Pharmacists are 
clearly suited to supporting this process 
by advising patients about the pros 
and cons of each therapy (warfarin and 
NOACs), and medication review offers 
several benefits. All patients with AF 
should also be counselled to optimise 
key behavioural and biomedical risk 
factors for cardiovascular disease, and 
to become aware of AF and stroke 
symptoms so that patients will act 
quickly to seek medical assistance 
if experienced. Where NOACs are 
indicated, medication reviews should 
also consider if the risk of bleeding can 
be further reduced (e.g. withdrawal of 
aspirin). When a NOAC is prescribed, 
advise patients of the need to take 
rivaroxaban 15 mg and 20 mg with food, 
or to take dabigatran or apixaban twice 
daily. Counsel patients regarding the 
common side effects of therapy used 
– particularly signs of bleeding such as 
unexplained bruising, bleeding, pink, 
red or dark brown urine, or red or black 
faeces– and advise them to tell other 
health professionals they see that they 
are taking warfarin or a NOAC. Because 
it is hygroscopic, pharmacists should 
ensure that dabigatran is not repacked 
into dose administration aids. In the 
longer-term, pharmacists need to be 
vigilant to potential adverse events and 
drug-drug interactions and to the need 
for possible dose reductions as kidney 
function declines in particular for ageing 
patients. Ensuring dose adjustments for 
key vulnerable groups, identifying the 
potential risk of drug-drug interactions, 
and supporting patients in terms of 
education and monitoring is an essential 
part of a pharmacist’s role. Data on 
NOACs is growing but these agents are 
still relatively understudied, hence all 
clinicians involved with patient care 
should be aware of the potential risks 
and monitor progress of the patients. 
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1.  Which of the following statements is 
true regarding stroke risk in patients 
AF?
a) AF increases the risk of stroke by 5 to 6 fold.
b) The majority of strokes are a direct result 
of AF.
c) Patients with paroxysmal AF are not at 
an increased risk of stroke.
d) Stroke is the leading cause of death in 
Australia.
2.  Which of the following is an important 
counselling point for NOACs?
a) Rivaroxaban 20 mg is best taken on an 
empty stomach. 
b) Apixaban should not be repacked into 
dose administration aids.
c) Dabigatran should be taken once daily.
d) Tell your doctor or pharmacist 
immediately if you have any unexplained 
bruising, bleeding, pink, red or dark 
brown urine, or red or black faeces.
3.  A physician telephones you to obtain 
dosing advice for a patient with 
non-valvular AF who he would like 
to start on  a NOAC. You note the 
patient’s creatinine clearance to be 
20 mL/min. What treatment  would 
you suggest?
a) Dabigatran 110 mg twice daily. 
b) Rivaroxaban 15 mg daily.
c) Apixaban 2.5 mg twice daily.
d) None of the above. Consider warfarin 
therapy only.
4.  A 75-year-old female well known to 
your pharmacy comes in and tells 
you she has a new diagnosis of atrial 
fibrillation. Her doctor has suggested 
that she needs anticoagulation to 
prevent blood clots. The patient has 
diabetes and a previous myocardial 
infarction. Calculate this patient’s 
CHA
2
DS
2
-VASc score. 
a) 1.
b) 3.
c) 4.
d) 5.
5.  A patient presents to your pharmacy 
with a prescription for itraconazole 
100 mg daily for four weeks. 
The patient states they have been 
prescribed this for the management 
of a fungal infection on their feet. 
You review the patient’s medication 
profile and note the patient is on 
apixaban 5 mg twice daily. Which of 
the following would be the safest 
course of action?
a) Dispense itraconazole therapy. No drug 
interaction is identified.
b) There is a minor drug interaction which 
requires a dose reduction of apixaban to 
2.5 mg twice.
c) Drug interaction identified, recommend 
changing itraconazole to fluconazole.
d) Drug interaction identified, recommend 
changing apixaban to rivaroxaban 
20 mg daily. 
To submit answers go to: www.psa.org.
au/education/submit-answers-online, and 
click on Australian Pharmacist.  
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